Articles from Modella AI

Modella AI, a leader in generative and agentic artificial intelligence for biomedicine, and illumiSonics Inc., a leader in label-free optical imaging and computational pathology, today announced successful research demonstrating compatibility between illumiSonics’ research-use only Multi-Laser Imaging (MLI™) system and Modella AI’s research-use only PathChat™ DX platform, which has been granted a Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). These novel study findings support the potential of an end-to-end, fully digital pathology workflow—from label-free tissue imaging to AI-enabled diagnostic interpretation—conducted without chemical staining or tissue damage.

Modella AI, a leader in artificial intelligence for life sciences, today announced a multi-year agreement with AstraZeneca. Under the agreement, Modella AI will provide access to its state-of-the-art multi-modal AI foundation models to AstraZeneca. This agreement aims to harness Modella AI’s advanced foundation models, capable of rich feature extraction from diverse data types, to accelerate clinical development across AstraZeneca’s global oncology portfolio.

Modella AI, a pioneer in generative and agentic artificial intelligence for biomedicine, is proud to announce that its cutting-edge generative AI co-pilot, PathChat DX, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). This recognition underscores PathChat DX’s potential to transform diagnostic workflows and improve patient outcomes in pathology.